The functional state of the complement system in leprosy

American Journal of Tropical Medicine and Hygiene

Volumn 78, Issue 4, 2008, Pages 605-610

  Gomes, Gabriela I ^a   Nahn Jr , Edilbert P ^b   Santos, Rose K R G ^a   Da Silva, Wilmar D ^a   Kipnis, Thereza L ^a  

^a Campos Dos Goytacazes   (Brazil)

^b Hospital M Ferreira Machado   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN;

ADULT; ARTICLE; BLOOD SAMPLING; COMPLEMENT SYSTEM; CONTROLLED STUDY; DIMORPHIC LEPROSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYSIS; HUMAN; IMMUNOCHEMISTRY; LEPROMATOUS LEPROSY; LEPROSY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM LEPRAE; TUBERCULOID LEPROSY;

MYCOBACTERIUM LEPRAE;

EID: 45349088686     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2008.78.605     Document Type: Article

References (26)

1. World Health Organization Study Group, 1982. Chemotherapy of leprosy for control programs. WHO Tech. Rep. Ser. no. 675. World Health Organization, Geneva.
2. Bleharski JR, Li H, Meinken C, Graeber TG, Ochoa M-T, Yamamura M, Burdick A, Sarno EN, Wagner M, Rollinghoff M, Rea TH, Colonna M, Stenger S, Bloom B, Eisenberg D, Modlin RL, 2003. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 301: 1527-1530.
3. Ridley DS, Jopling WH, 1966. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255-273.
4. Kaplan G, 1993. Recent advances in cytokine therapy in leprosy. J Infect Dis 167 (Suppl 1): 18-22.
5. Norman G, Joseph G, Richard J, 2004. Validity of the WHO operational classification and value of other clinical signs in the classification of leprosy. Int J Lepr Other Mycobact Dis 72: 278-283.
6. Naafs B, 2000. Current views on reactions in leprosy. Ind J Leprosy 72: 97-122.
7. Chakrabarty AR, Maire M, Saha K, Lambert PH, 1983. Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immunecomplexes isolated from sera of lepromatous patients. Clin Exp Immunol 51: 225-231.
8. Ramanathan VD, Parkash O, Ramu G, Parker D, Curtis J, Sengupta U, Turk JL, 1984. Isolation and analysis of circulating immune complexes isolated of circulating immune complexes in leprosy. Clin Immunol Immunopath 32: 261-268.
9. Schifferly JA, Bartolutti SR, Peters DK, 1980. Inhibition of immune precipitation by complement. Clin Exp Immunol 42: 387-394.
10. Miller GW, Nussenzweig VA, 1975. A new complement function: solubilization of antibody-antibody aggregates. Proc Natl Acad Sci USA 72: 418-122.
11. Walport M, 2001. Complement: first of two parts. N Engl J Med 344: 1058-1066.
12. Walport M, 2001. Complement: second of two parts. N Engl J Med 344: 1140-1144.
13. Fugita T, Matsushita M, Endo Y, 2004. The lectin-complement pathway: its role in inate immunity and evolution. Immunol Rev 198: 185-202.
14. Tyagi P, Ramanathan VD, Girdhar BK, Katoch K, Bhatia AS, Sengupta U, 1990. Activation of complement by circulating immune complexes isolated from leprosy patients. Int J Lepr Other Mycobact Dis 58: 31-38.
15. Schlesinger LS, Horwitz MA, 1990. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. J Clin Invest 85: 1304-1314.
16. Rapp HJ, Borsos T, 1970. Molecular Basis of Complement Action. New York: Appleton-Century-Crofts.
17. Zwirner J, Wittig A, Kremmer E, Götze O, 1998. A novel ELISA for the evaluation of the classical pathway of complement. J Immunol Methods 211: 183-190.
18. Bjorvatan B, Barnetson RS, Kronvall G, Zubler RH, Lambert PH, 1976. Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol 26: 388-396.
19. Jack DL, Klein N, Turner MW, 2001. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 180: 86-99.
20. Turner MW, 2003. The role of mannose binding lectin in health and disease. Mol Immunol 40: 423-429.
21. Chattergee D, Khoo KH, 1998. Mycobacterial lipoarabinomannan: an extraorduinary lipoheroglycan with profound physiological effects. Glycobiology 8: 113-120.
22. Dornelles LN, Pereira-Ferrari L, Messias-Reason I, 2006. Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms. Clin Exp Immunol 145: 463-468.
23. Kilpatrick DC, 2002. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 1572: 104-113.
24. Saha K, Chakraborty AK, 1977. Serum complement profile in leprosy and its comparison with immune complexe diseases. Int J Lepr Mycobact Dis 45: 327-337.
25. Saha K, Sharma V, Chakrabarty AK, Sehgal VN, 1983. Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Scand J Immunol 17: 37-43.
26. Thurman JM, Holers VM, 2006. The central role of the alternative complement pathway in human disese. J Immunol 176: 1305-1310.